TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04119492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP Treatment Group
Description: Cognitive Orientation to Occupational Performance (CO-OP) is a cognitive approach to solving functional motor problems (Polatajko et al., 2001). Therapists teach children a global problem-solving strategy (Goal-Plan-Do-Check) as means to develop specific strategies for overcoming motor problems; the strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists trained in CO-OP will see children for one hour, once weekly for 10 weeks. Parents or caregivers will be encouraged to attend treat¬ment sessions so therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select 3 functional motor goals to be addressed during treatment.
Study: NCT03775265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo 3DCRT or IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo 3DCRT or IMRT
Study: NCT03181217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 22
Description: 300 ml tap water at 22 ºC with 75 grams of glucose added

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 22
Description: 300 ml tap water at 22 ºC with 75 grams of glucose added

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 22
Description: 300 ml tap water at 22 ºC with 75 grams of glucose added
Study: NCT00061815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 85 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 200 mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: 200 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400 mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 400 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 600 mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 600 mg/m2 IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 250 mg/m2 IV
Study: NCT04685005

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wake Up
Description: The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wake Up
Description: The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wake Up
Description: The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wake Up
Description: The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wake Up
Description: The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: Caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine
Study: NCT04219696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reactive balance training
Description: A research physiotherapist will oversee reactive balance training (RBT) to ensure consistent RBT delivery across participants. Training strategies will be individualized to each participant, based on their balance impairments and rehabilitation goals. The RBT program includes multi-directional 'internal' and 'external' balance perturbations. Internal perturbations are achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task (e.g., kicking a soccer ball). External perturbation are delivered manually using a push or pull from the physiotherapist. As participants improve their reactive balance control, difficulty will be increased by shifting task requirements along a continuum from stable to mobile, and from predictable to unpredictable, and by increasing perturbation magnitude or imposing sensory or environmental challenges.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reactive balance training
Description: A research physiotherapist will oversee reactive balance training (RBT) to ensure consistent RBT delivery across participants. Training strategies will be individualized to each participant, based on their balance impairments and rehabilitation goals. The RBT program includes multi-directional 'internal' and 'external' balance perturbations. Internal perturbations are achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task (e.g., kicking a soccer ball). External perturbation are delivered manually using a push or pull from the physiotherapist. As participants improve their reactive balance control, difficulty will be increased by shifting task requirements along a continuum from stable to mobile, and from predictable to unpredictable, and by increasing perturbation magnitude or imposing sensory or environmental challenges.
Study: NCT02603601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body lifestyle intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard lifestyle intervention
Study: NCT04418869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise bouts
Description: Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
Study: NCT02901587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 (10 mg/day)
Description: tablets for oral administration once daily
Study: NCT02433587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients will take Aspirin 81 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients will take Aspirin 81 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients will take Clopidogrel 75 mg
Study: NCT02901587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 (30 mg/day)
Description: tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine (Seroquel XR® 800 mg/day)
Description: tablets for oral administration once daily
Study: NCT05046067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery per standard of care
Study: NCT02270528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (\~5 minutes)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (\~5 minutes)
Study: NCT02164812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Study: NCT03677505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KoMAC videolaryngoscope
Description: Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope
Description: Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
Study: NCT03942848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zicotinide followed by placebo
Description: The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
Study: NCT04219696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reactive balance training
Description: A research physiotherapist will oversee reactive balance training (RBT) to ensure consistent RBT delivery across participants. Training strategies will be individualized to each participant, based on their balance impairments and rehabilitation goals. The RBT program includes multi-directional 'internal' and 'external' balance perturbations. Internal perturbations are achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task (e.g., kicking a soccer ball). External perturbation are delivered manually using a push or pull from the physiotherapist. As participants improve their reactive balance control, difficulty will be increased by shifting task requirements along a continuum from stable to mobile, and from predictable to unpredictable, and by increasing perturbation magnitude or imposing sensory or environmental challenges.
Study: NCT02270528

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Task
Description: The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Task
Description: The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Task
Description: The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
Study: NCT01258790

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
Study: NCT03942848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: zicotinide followed by placebo
Description: The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo followed by zicotinide
Description: The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo followed by zicotinide
Description: The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
Study: NCT00540826

Intervention type: DRUG
Intervention: Atomoxetine
Description: in-label use

Intervention type: DRUG
Intervention: stimulants (any approved ADHD medication)
Description: in-label use
Study: NCT01259908

Intervention type: PROCEDURE
Intervention: Laparoscopic vs open Ygraft
Description: Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
Study: NCT01103791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
Study: NCT04140591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proton-pump inhibitor
Description: PPI: Pariet EC 20mg/QDAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol+Proton-pump inhibitor
Description: Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure \>90mmHg) PPI: Pariet EC 20mg/QDAC
Study: NCT03649750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex®
Description: Mucinex® 600 mg ER bi-layer tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex®
Description: Mucinex® 600 mg ER bi-layer tablets
Study: NCT02433587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients will take Clopidogrel 75 mg
Study: NCT01258790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
Study: NCT00883818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin, doxycycline
Description: azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g
Study: NCT02241733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing retraining plus exercise
Description: Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise only
Description: Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
Study: NCT00671892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide endotoxin
Description: Delivered in nebulized form expressed in activity units(endotoxin units -EU).~Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:~Challenge One first saline then 5000 EU 10,000 EU 20,000 EU~Challenge 1 and 2 must be at least 2 weeks apart.~Challenge 2 Saline 40,000 EU 80,000 EU
Study: NCT03459248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual therapy
Description: combination of 10 mg metoclopramide with 4 mg ondansetron

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy
Description: 10 mg metoclopramide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Induction of general anesthesia will be performed followed by endotracheal intubation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction of general anesthesia will be performed followed by endotracheal intubation.
Study: NCT03081065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
Study: NCT02915276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blastocentisis
Description: Removal of blastocoelic fluid from the blastocoelic cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trophectoderm biopsy
Description: Removal of trophectoderm cells from the blastocyst
Study: NCT04802460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset (The Guided Meditation VR App through Oculus Go headset)
Description: Patients assigned to the VR condition will engage with the VR using The Guided Meditation VR App through Oculus Go headset. They will enjoy up to a 10 minute video of an environment of their choosing. During this video they will listen to calming music and a guided meditation session.
Study: NCT02176330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePAQ-PF followed by a telephone consultation.
Description: All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ePAQ-PF followed by a face to face consultation
Description: All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
Study: NCT02299297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Dosage/Frequency: 5mg - 10mg, oral, twice daily
Study: NCT03951844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRIDGE/EMPATIA exoskeleton
Description: The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
Study: NCT03789318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008 5 mg
Description: 5 mg CA-008 reconstituted in saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each cohort will use placebo reconstituted in saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each cohort will use placebo reconstituted in saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% administered pre-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% administered pre-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% administered pre-surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% administered pre-surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% administered pre-surgery
Study: NCT00192218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist
Description: 0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
Study: NCT01908491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IV PCA
Description: On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
Study: NCT03107169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: Patients in the FMT group received FMT-FURM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)